Literature DB >> 8249436

Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination.

T M Kündig1, C P Kalberer, H Hengartner, R M Zinkernagel.   

Abstract

The effects of immunity to vaccinia virus on the efficiency of vaccination with a vaccinia recombinant virus were studied. In mice the efficiency and duration of the B-cell response to the recombinant gene product of a second vaccinia recombinant virus were suppressed for more than 9 months, i.e. practically lifelong. Antibody titres against the recombinant gene product were not only lower but also lasted for a shorter time. Thus, immunity to vaccinia virus may influence both the titre and duration of the antibody response induced by a second distinct vaccinia recombinant vaccine.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8249436     DOI： 10.1016/0264-410x(93)90079-d

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  27 in total

1.  Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.

Authors:  J C Ramírez; M M Gherardi; D Rodríguez; M Esteban
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 4.  Viral vector-based therapeutic cancer vaccines.

Authors:  Cecilia Larocca; Jeffrey Schlom
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

5.  The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cells.

Authors:  Matthew D Martin; Thomas C Wirth; Peter Lauer; John T Harty; Vladimir P Badovinac
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

6.  Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response.

Authors:  H G Bouwer; H Shen; X Fan; J F Miller; R A Barry; D J Hinrichs
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

7.  An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Authors:  Michael A Morse; Amy C Hobeika; Takuya Osada; Peter Berglund; Bolyn Hubby; Sarah Negri; Donna Niedzwiecki; Gayathri R Devi; Bruce K Burnett; Timothy M Clay; Jonathan Smith; H Kim Lyerly
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

8.  Vaccines as monotherapy and in combination therapy for prostate cancer.

Authors:  Julia Rotow; Sofia R Gameiro; Ravi A Madan; James L Gulley; Jeffrey Schlom; James W Hodge
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

9.  Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice.

Authors:  Timo Fischer; Oliver Planz; Lothar Stitz; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.